C07K 2319/95
Containing a motif/fusion for degradation
Official title: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
C07K2319/95 (Containing a motif/fusion for degradation) appears on 220 US grants and 351 published applications in this corpus.
Search patents in C07K- Granted patents
- 220
- Published applications
- 351
- Assignees
- 211
- Inventors
- 796
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 12 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 8 |
| 2004 | 1 | 5 |
| 2005 | 3 | 9 |
| 2006 | 2 | 3 |
| 2007 | 4 | 3 |
| 2008 | 5 | 0 |
| 2009 | 1 | 6 |
| 2010 | 3 | 6 |
| 2011 | 2 | 3 |
| 2012 | 5 | 6 |
| 2013 | 3 | 7 |
| 2014 | 5 | 13 |
| 2015 | 6 | 11 |
| 2016 | 5 | 9 |
| 2017 | 9 | 18 |
| 2018 | 6 | 20 |
| 2019 | 8 | 21 |
| 2020 | 12 | 20 |
| 2021 | 25 | 27 |
| 2022 | 11 | 37 |
| 2023 | 7 | 28 |
| 2024 | 12 | 31 |
| 2025 | 16 | 34 |
| 2026 | 19 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Regulated synthetic gene activation systems18 Aug 2026US 12,709,637 B2Trustees of Boston University
- CA2-IL15 fusion proteins for tunable regulation2 Jun 2026US 12,642,792 B2Obsidian Therapeutics, Inc.
- Engineered MCP and PCP proteins and systems and methods thereof26 May 2026US 12,637,493 B2Trustees of Boston University
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
- Programmable miRNA-Dependent Gene Expression1 Oct 2026US 2026/0295089 A1New York University
- Binder and fusion protein targeting pcna, and uses thereof24 Sep 2026US 2026/0285916 A1Hubei University
- Use of chimera in targeted protein degradation technology17 Sep 2026US 2026/0274986 A1Sun Yat-Sen University
- Expression cassette combination and use thereof3 Sep 2026US 2026/0258112 A1
Most cited
By later US patents
- Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases143US 8,956,828 B2Ospedale San Raffaele S.R.L. · 2015
- Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein139US 5,834,247 ANew England Biolabs, Inc. · 1998
- Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same113US 9,500,653 B2Yale University · 2016
- Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same109US 9,632,089 B2Yale University · 2017
- Expression of fusion polypeptides transported out of the cytoplasm without leader sequences85US 5,914,254 ACeltrix Pharmaceuticals, Inc. · 1999